Trial
NCT00843310
Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
NYU Langone Health
Collaborators
Celgene
Condition
Multiple Myeloma
Intervention
Lenalidomide (Revlimid)
Why stopped
Due to slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-07-19